2017
Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
del Mar Castro M, Gomez MA, Kip AE, Cossio A, Ortiz E, Navas A, Dorlo TP, Saravia NG. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.02198-16. PMID: 27956421, PMCID: PMC5328512, DOI: 10.1128/aac.02198-16.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisMiltefosine concentrationsPeripheral blood mononuclear cellsInitiation of treatmentCompletion of treatmentBlood mononuclear cellsEnd of treatmentOutcome of treatmentConcentration-time curvePharmacokinetic clinical trialsClinical responsePediatric patientsPediatric populationMononuclear cellsTherapeutic regimensDrug exposureClinical trialsNoncompartmental analysisParasite eliminationTherapeutic outcomesStudy participantsMiltefosinePatientsLiquid chromatography-tandem mass spectrometryPK differences
2015
Cost-Effectiveness of Meglumine Antimoniate and Caretaker Directly Observed Treatment Miltefosine Treatment for Cutaneous Leishmaniasis for Pediatric Patients in Colombia
Berger B, Cossio A, Pho M, Del Mar Castro M, Prada S, Guerrero R, Bartlett A, Saravia N. Cost-Effectiveness of Meglumine Antimoniate and Caretaker Directly Observed Treatment Miltefosine Treatment for Cutaneous Leishmaniasis for Pediatric Patients in Colombia. Open Forum Infectious Diseases 2015, 2: 115. DOI: 10.1093/ofid/ofv131.35.Peer-Reviewed Original Research